{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:13:27Z","timestamp":1789985607252,"version":"4.0.1"},"reference-count":56,"publisher":"International Society of Global Health","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Glob Health"],"DOI":"10.7189\/jogh.15.04229","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T06:52:46Z","timestamp":1755845566000},"source":"Crossref","is-referenced-by-count":5,"title":["Impact of pooled procurement of medicines on patient adherence and economic burden: evidence from China"],"prefix":"10.7189","volume":"15","author":[{"given":"Boya","family":"Zhao","sequence":"first","affiliation":[{"name":"School of Public Health, Peking University, Beijing, China"},{"name":"School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China"},{"name":"Department Centre for Social Science Survey and Data, Tianjin University, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Cheng","sequence":"additional","affiliation":[{"name":"School of Public Health, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing Lin","family":"Feng","sequence":"additional","affiliation":[{"name":"School of Public Health, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4223","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"key-10.7189\/jogh.15.04229-202508220825-R1","unstructured":"World Health Organization. WHO guideline on country pharmaceutical pricing policies. 2nd ed. Geneva, Switzerland: World Health Organization; 2020."},{"key":"key-10.7189\/jogh.15.04229-202508220825-R2","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.socscimed.2012.05.044","article-title":"The logical underpinnings and benefits of pooled pharmaceutical procurement: a pragmatic role for our public institutions?","volume":"75","author":"Huff-Rousselle","year":"2012","journal-title":"Soc Sci Med"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R3","doi-asserted-by":"publisher","DOI":"10.1002\/hec.3788","article-title":"The effect of group purchasing on prices hospitals pay for medicines.","author":"Toulemon","year":"2018","journal-title":"Health Econ"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4103\/2224-3151.206625","article-title":"A cross-sectional survey of the models in Bihar and Tamil Nadu, India for pooled procurement of medicines.","volume":"4","author":"Chokshi","year":"2015","journal-title":"WHO South-East Asia J Public Health"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R5","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1097\/QAI.0000000000000053","article-title":"Trends in procurement costs for HIV commodities: a 7-year retrospective analysis of global fund data across 125 countries.","volume":"65","author":"Wafula","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R6","first-page":"429","article-title":"E-procurement in the Brazilian healthcare system: the impact of joint drug purchases by a hospital network.","volume":"26","author":"Sigulem","year":"2009","journal-title":"Rev Panam Salud Publica"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R7","doi-asserted-by":"publisher","first-page":"e00552","DOI":"10.1002\/prp2.552","article-title":"Evaluating the centralized purchasing policy for the treatment of hepatitis C: The Colombian CASE.","volume":"7","author":"P\u00e9rez","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R8","doi-asserted-by":"publisher","first-page":"e005519","DOI":"10.1136\/bmjgh-2021-005519","article-title":"Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement (NVBP) effect in China.","volume":"6","author":"Yuan","year":"2021","journal-title":"BMJ Glob Health"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/(SICI)1099-1751(199604)11:2<135::AID-HPM422>3.0.CO;2-1","article-title":"Cost Containment through Pharmaceutical Procurement: A Caribbean Case Study.","volume":"11","author":"Huff-Rousselle","year":"1996","journal-title":"Int J Health Plann Manage"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R10","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/heapol\/czw165","article-title":"Can voluntary pooled procurement reduce the price of antiretroviral drugs? a case study of Efavirenz.","volume":"32","author":"Kim","year":"2017","journal-title":"Health Policy Plan"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R11","doi-asserted-by":"publisher","first-page":"7724","DOI":"10.34172\/ijhpm.2023.7724","article-title":"Impact of China\u2019s National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: An Interrupted Time Series Analysis in Tianjin.","volume":"12","author":"Zhao","year":"2023","journal-title":"Int J Health Policy Manag"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R12","doi-asserted-by":"publisher","first-page":"e054346","DOI":"10.1136\/bmjopen-2021-054346","article-title":"Impact of \u20184+7\u2019 volume-based drug procurement on the use of policy-related original and generic drugs: a natural experimental study in China.","volume":"12","author":"Wang","year":"2022","journal-title":"BMJ Open"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R13","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1377\/hlthaff.2015.1624","article-title":"Early Impact Of The Affordable Care Act On Oral Contraceptive Cost Sharing, Discontinuation, And Nonadherence.","volume":"35","author":"Pace","year":"2016","journal-title":"Health Aff (Millwood)"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R14","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1377\/hlthaff.2010.0571","article-title":"Copayment reductions generate greater medication adherence in targeted patients.","volume":"29","author":"Maciejewski","year":"2010","journal-title":"Health Aff (Millwood)"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.18553\/jmcp.2022.21270","article-title":"Cost-sharing and adherence, clinical outcomes, health care utilization, and costs: A systematic literature review.","volume":"29","author":"Fusco","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R16","first-page":"837","article-title":"How payment scheme affects patients\u2019 adherence to medications? A systematic review.","volume":"10","author":"Aziz","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R17","doi-asserted-by":"publisher","first-page":"e13779","DOI":"10.1111\/cts.13779","article-title":"Generic substitution of amlodipine is not associated with increased risk of mortality or adverse cardiovascular events: An observational cohort study.","volume":"17","author":"Zhao","year":"2024","journal-title":"Clin Transl Sci"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R18","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s40258-018-0405-7","article-title":"Shaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage.","volume":"16","author":"Maniadakis","year":"2018","journal-title":"Appl Health Econ Health Policy"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R19","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/0167-6296(91)90022-F","article-title":"Physician response to fee changes with multiple payers.","volume":"10","author":"McGuire","year":"1991","journal-title":"J Health Econ"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1093\/heapol\/czae101","article-title":"Testing the unintended cost effects of health policies for generic substitutions: the case of China\u2019s National Volume-Based Procurement (NVBP) policy.","volume":"40","author":"Zhao","year":"2025","journal-title":"Health Policy Plan"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/jcpt.13551","article-title":"Impact of the National Centralized Drug Procurement Policy (4 + 7 policy) on the drug expenditures of patients treated in outpatient and emergency departments in a large tertiary level-A hospital in China: A single centre, interrupted time series.","volume":"47","author":"Lan","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R22","doi-asserted-by":"publisher","first-page":"1405197","DOI":"10.3389\/fpubh.2024.1405197","article-title":"National centralized drug procurement and health care expenditure of households-micro-evidence from CFPS.","volume":"12","author":"Li","year":"2024","journal-title":"Front Public Health"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R23","doi-asserted-by":"publisher","first-page":"1302154","DOI":"10.3389\/fphar.2024.1302154","article-title":"Impacts of national volume-based drug procurement policy on the utilization and costs of antihypertensive drugs in a Chinese medicine hospital: an interrupted time series analysis of 5138 patients.","volume":"15","author":"Shang","year":"2024","journal-title":"Front Pharmacol"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R24","first-page":"603","article-title":"[Chinese guidelines for the management of hypertension (2024 update).]","volume":"32","author":"Writing Group of Chinese Guideline for the Management of Hypertension","year":"2024","journal-title":"Chin J Hypertens"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R25","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1002\/hpm.3429","article-title":"The impact of National Centralised Drug Procurement policy on the use of policy-related original and generic drugs in China.","volume":"37","author":"Yang","year":"2022","journal-title":"Int J Health Plann Manage"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R26","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs.","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/rheumatology\/kez320","article-title":"Methodological considerations when analysing and interpreting real-world data.","volume":"59","author":"St\u00fcrmer","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R28","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/pds.5258","article-title":"New-user and prevalent-user designs and the definition of study time origin in pharmacoepidemiology: A review of reporting practices.","volume":"30","author":"Luijken","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3122\/jabfm.2007.01.060094","article-title":"Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies.","volume":"20","author":"Elliott","year":"2007","journal-title":"J Am Board Fam Med"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R30","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1185\/03007995.2014.964853","article-title":"A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy.","volume":"30","author":"Xie","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R31","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12913-023-09077-4","article-title":"Patients\u2019 attitudes towards switching to national volume-based procurement (NVBP) Drugs-a qualitative investigation in Wuhan, China.","volume":"23","author":"Tao","year":"2023","journal-title":"BMC Health Serv Res"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R32","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.2147\/PPA.S368784","article-title":"A Critical Review of Medication Adherence in Hypertension: Barriers and Facilitators Clinicians Should Consider.","volume":"16","author":"Hamrahian","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R33","doi-asserted-by":"publisher","first-page":"100021","DOI":"10.1016\/j.hpopen.2020.100021","article-title":"Assessing the design of China\u2019s complex health system - Concerns on equity and efficiency.","volume":"1","author":"Wang","year":"2020","journal-title":"Health Policy OPEN"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R34","doi-asserted-by":"publisher","first-page":"520","DOI":"10.2471\/BLT.08.058925","article-title":"Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases.","volume":"87","author":"Waning","year":"2009","journal-title":"Bull World Health Organ"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R35","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1186\/1471-2458-9-S1-S6","article-title":"Factors influencing global antiretroviral procurement prices.","volume":"9","author":"Wirtz","year":"2009","journal-title":"BMC Public Health"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R36","doi-asserted-by":"publisher","first-page":"e16116","DOI":"10.1097\/MD.0000000000016116","article-title":"Determinants of hypertension treatment adherence among a Chinese population using the therapeutic adherence scale for hypertensive patients.","volume":"98","author":"Pan","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R37","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2147\/PPA.S243665","article-title":"Analysis of Adherence to Antihypertensive Drugs in Chinese Patients with Hypertension: A Retrospective Analysis Using the China Health Insurance Association Database.","volume":"14","author":"Cui","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R38","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/jhh.2008.83","article-title":"Patterns of antihypertensive prescribing, discontinuation and switching among a Hong Kong Chinese population from over one million prescriptions.","volume":"22","author":"Wong","year":"2008","journal-title":"J Hum Hypertens"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R39","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2147\/PPA.S459678","article-title":"Medication Adherence of Older Adults with Hypertension: A Systematic Review.","volume":"18","author":"Ruksakulpiwat","year":"2024","journal-title":"Patient Prefer Adherence"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R40","doi-asserted-by":"publisher","first-page":"e026582","DOI":"10.1161\/JAHA.122.026582","article-title":"Global Burden, Regional Differences, Trends, and Health Consequences of Medication Nonadherence for Hypertension During 2010 to 2020: A Meta-Analysis Involving 27 Million Patients.","volume":"11","author":"Lee","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R41","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12872-025-04538-6","article-title":"The link between adherence to antihypertensive medications and mortality rates in patients with hypertension: a systematic review and meta-analysis of cohort studies.","volume":"25","author":"Peng","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R42","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1590\/S0034-89102011005000016","article-title":"Municipal consortia for medicine procurement: impact on the stock-out and budget.","volume":"45","author":"Amaral","year":"2011","journal-title":"Rev Saude Publica"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R43","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1524-4733.2005.04040.x","article-title":"Managing prices for hospital pharmaceuticals: a successful strategy for New Zealand?","volume":"8","author":"Tordoff","year":"2005","journal-title":"Value Health"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R44","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0167-6296(98)00024-1","article-title":"Physician response to Medicare fee reductions: changes in the volume of coronary artery bypass graft (CABG) surgeries in the Medicare and private sectors.","volume":"17","author":"Yip","year":"1998","journal-title":"J Health Econ"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R45","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1023\/A:1020436509217","article-title":"Spillover effects of Medicare fee reductions: evidence from ophthalmology.","volume":"2","author":"Mitchell","year":"2002","journal-title":"Int J Health Care Finance Econ"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R46","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1377\/hlthaff.2009.0563","article-title":"How Medicare\u2019s payment cuts for cancer chemotherapy drugs changed patterns of treatment.","volume":"29","author":"Jacobson","year":"2010","journal-title":"Health Aff (Millwood)"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R47","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jhealeco.2012.06.001","article-title":"Hospital volume responses to Medicare\u2019s Outpatient Prospective Payment System: evidence from Florida.","volume":"31","author":"He","year":"2012","journal-title":"J Health Econ"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R48","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.socscimed.2018.06.007","article-title":"Intended and unintended impacts of price changes for drugs and medical services: Evidence from China.","volume":"211","author":"Fu","year":"2018","journal-title":"Soc Sci Med"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R49","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1377\/hlthaff.2014.1114","article-title":"Intended and unintended consequences of China\u2019s zero markup drug policy.","volume":"34","author":"Yi","year":"2015","journal-title":"Health Aff (Millwood)"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R50","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/wmh3.222","article-title":"Patient Copayments, Provider Incentives and Income Effects: Theory and Evidence from the Essential Medications List under China\u2019s 2009 Healthcare Reform.","volume":"9","author":"Chen","year":"2017","journal-title":"World Med Health Policy"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R51","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12939-020-01363-5","article-title":"Does the separating of hospital revenue from drug sales reduce the burden on patients? Evidence from China.","volume":"20","author":"Li","year":"2021","journal-title":"Int J Equity Health"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R52","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/CIRCULATIONAHA.108.830299","article-title":"Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients.","volume":"120","author":"Mazzaglia","year":"2009","journal-title":"Circulation"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R53","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.jacc.2016.11.034","article-title":"Improving Medication Adherence in Cardiometabolic Disease: Practical and Regulatory Implications.","volume":"69","author":"Ferdinand","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R54","article-title":"Medication adherence in cardiovascular medicine.","volume":"374","author":"Simon","year":"2021","journal-title":"BMJ"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R55","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1161\/CIRCRESAHA.118.313220","article-title":"Adherence in Hypertension.","volume":"124","author":"Burnier","year":"2019","journal-title":"Circ Res"},{"key":"key-10.7189\/jogh.15.04229-202508220825-R56","doi-asserted-by":"publisher","first-page":"S172","DOI":"10.1016\/j.amepre.2017.07.014","article-title":"Comorbidity Status and Annual Total Medical Expenditures in U.S. Hypertensive Adults.","volume":"53","author":"Park","year":"2017","journal-title":"Am J Prev Med"}],"container-title":["Journal of Global Health"],"original-title":[],"link":[{"URL":"https:\/\/jogh.org\/2025\/jogh-15-04229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T06:52:48Z","timestamp":1755845568000},"score":1,"resource":{"primary":{"URL":"https:\/\/jogh.org\/2025\/jogh-15-04229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":56,"URL":"https:\/\/doi.org\/10.7189\/jogh.15.04229","relation":{},"ISSN":["2047-2978","2047-2986"],"issn-type":[{"value":"2047-2978","type":"print"},{"value":"2047-2986","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"article-number":"04229"}}